Implanet has announced the award of CE marking for the Jazz Cap System, developed to meet the constraints of vertebral fusion indications in adults.
Jazz Cap System, which was developed principally to facilitate the treatment of degenerative conditions in adult patients, is a proprietary solution for securing screws in poor-quality bone—a factor in 10—30% of vertebral fusion cases in adult patients. Jazz Cap System is a set of single-use sterile implants consisting of a screw and its Jazz Cap blocker, which incorporates the patented Jazz Lock system and a Jazz Band.
Régis Le Couëdic, Implanet’s head of research and development, commented: “As part of our ongoing innovation drive, we are working closely with surgeons to continually upgrade our Jazz range. The Jazz Cap System compliments our range perfectly, in line with our approach of covering all indications compatible with use of sublaminar bands. It will help meet demand from surgeons for screw securing solutions to better accommodate certain degenerative conditions. This functionality is protected by new and existing patents”.
Ludovic Lastennet, Implanet’s chief executive officer, added: “As promised, we have kept up our pace of innovation despite an increasingly challenging regulatory environment. The award of this new CE marking in record time is a ringing endorsement of our approach. Jazz Cap System addresses a market worth US$2.5 billion, four to five times the size of the spinal deformity market. The proprietary Jazz Cap System is designed for specific compatibility with a given fixation system, providing Implanet and its partners a significant competitive advantage in securing screws in poor-quality bones.”
